Education
About Us
Working with TipRanks
Follow Us
Astellas Pharma (JP:4503)
:4503
Total Valuation
Astellas Pharma has a market cap or net worth of ¥2.29T. The enterprise value is ¥3.60T.
Market Cap¥2.29T
Enterprise Value¥3.60T
Share Statistics
Astellas Pharma has 1.81B shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1.81B
Owened by Insiders
Owened by Instutions
Financial Efficiency
Astellas Pharma’s return on equity (ROE) is 0.01 and return on invested capital (ROIC) is 3.09%.
Return on Equity (ROE)1.07%
Return on Assets (ROA)0.48%
Return on Invested Capital (ROIC)3.09%
Return on Capital Employed (ROCE)5.46%
Revenue Per Employee¥126,584,722.787
Profits Per Employee-¥3,892,300.393
Employee Count14,754
Asset Turnover0.45
Inventory Turnover1.18
Valuation Ratios
The current PE Ratio of Astellas Pharma is 172.65. Astellas Pharma’s PEG ratio is -2.09.
PE Ratio172.65
PS Ratio1.84
PB Ratio1.84
Price to Fair Value1.84
Price to FCF32.71
Price to Operating Cash Flow17.06
PEG Ratio-2.09
Income Statement
In the last 12 months, Astellas Pharma had revenue of ¥1.87T and earned -¥57.43B in profits. Earnings per share was -¥32.02.
Revenue¥1.87T
Gross Profit¥1.46T
Operating Income¥35.38B
Pretax Income-¥74.79B
Net Income-¥57.43B
EBITDA330.35B
Earnings Per Share (EPS)-32.02
Cash Flow
In the last 12 months, operating cash flow was ¥170.47B and capital expenditures -¥47.23B, giving a free cash flow of ¥123.24B billion.
Operating Cash Flow¥170.47B
Free Cash Flow¥123.24B
Free Cash Flow per Share¥68.10
Dividends & Yields
Astellas Pharma pays an annual dividend of ¥37.00, resulting in a dividend yield of 5.57%
Dividend Per Share¥37.00
Dividend Yield5.57%
Payout Ratio-115.47%
Free Cash Flow Yield3.06%
Earnings Yield0.58%
Stock Price Statistics
Beta0.48
52-Week Price Change-8.01%
50-Day Moving Average1.42K
200-Day Moving Average1.55K
Relative Strength Index (RSI)62.92
Average Volume (3m)7.47M
Important Dates
Astellas Pharma upcoming earnings date is Apr 25, 2025, TBA.
Last Earnings DateFeb 4, 2025
Next Earnings DateApr 25, 2025
Ex-Dividend DateMar 28, 2025
Financial Position
Astellas Pharma as a current ratio of 0.93, with Debt / Equity ratio of 0.63
Current Ratio0.93
Quick Ratio0.74
Debt to Market Cap0.31
Net Debt to EBITDA3.43
Interest Coverage Ratio13.30
Taxes
In the past 12 months, Astellas Pharma has paid -¥20.55B in taxes.
Income Tax-¥20.55B
Effective Tax Rate31.74%
Enterprise Valuation
Astellas Pharma EV to EBITDA ratio is 18.49, with an EV/FCF ratio of 40.15.
EV to Sales2.25
EV to EBITDA18.49
EV to Free Cash Flow40.15
EV to Operating Cash Flow20.95
Balance Sheet
Astellas Pharma has ¥179.87B in cash and marketable securities with ¥915.36B in debt, giving a net cash position of ¥735.50B billion.
Cash & Marketable Securities¥179.87B
Total Debt¥915.36B
Net Cash¥735.50B
Net Cash Per Share¥406.43
Tangible Book Value Per Share-¥154.20
Margins
Gross margin is 81.76%, with operating margin of 7.77%, and net profit margin of 1.06%.
Gross Margin81.76%
Operating Margin7.77%
Pretax Margin1.56%
Net Profit Margin1.06%
EBITDA Margin12.18%
EBIT Margin2.31%
Analyst Forecast
The average price target for Astellas Pharma is ¥1875.45, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target¥1875.45
Price Target Upside47.73%
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast21.01%
EPS Growth Forecast-12669.88%